Gennova Biopharmaceuticals granted conditional permission for human clinical trial of its COVID-19 vaccine

The recommendations of the Subject Expert Committee (SEC) on COVID-19, which deliberated upon the proposal submitted by the firm for grant of permission to conduct phases 1 and 2 clinical trials along with animal toxicity study data, has been approved by DCGI.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news